Nature:丙肝病毒阳离子通道的结构被揭示

2013-07-27 Nature Nature

丙肝病毒 (HCV) 是肝病和肝癌的一个主要病因。由于没有保护性疫苗,也由于治疗方案仍然有限,寻找新的治疗目标便显得很重要。James Chou及其同事在这篇论文中报告了低聚丙肝病毒“viroporin p7”的结构,是通过NMR谱获得的。该蛋白能自组成一个可传导阳离子的通道复合物。该通道六聚物的一个高分辨率视图显示了新颖的漏斗状通道结构,而功能研究则识别出了对通道活性重要的残体。 英文摘要:

丙肝病毒 (HCV) 是肝病和肝癌的一个主要病因。由于没有保护性疫苗,也由于治疗方案仍然有限,寻找新的治疗目标便显得很重要。James Chou及其同事在这篇论文中报告了低聚丙肝病毒“viroporin p7”的结构,是通过NMR谱获得的。该蛋白能自组成一个可传导阳离子的通道复合物。该通道六聚物的一个高分辨率视图显示了新颖的漏斗状通道结构,而功能研究则识别出了对通道活性重要的残体。

英文摘要:

Nature    doi:10.1038/nature12283

Unusual architecture of the p7 channel from hepatitis C virus

Bo OuYang,Shiqi Xie,Marcelo J. Berardi,Xinhao Zhao, Jyoti Dev, Wenjing Yu,Bing Sun  & James J. Chou

The hepatitis C virus (HCV) has developed a small membrane protein, p7, which remarkably can self-assemble into a large channel complex that selectively conducts cations. We wanted to examine the structural solution that the viroporin adopts in order to achieve selective cation conduction, because p7 has no homology with any of the known prokaryotic or eukaryotic channel proteins. The activity of p7 can be inhibited by amantadine and rimantadine, which are potent blockers of the influenza M2 channel and licensed drugs against influenza infections. The adamantane derivatives have been used in HCV clinical trials, but large variation in drug efficacy among the various HCV genotypes has been difficult to explain without detailed molecular structures. Here we determine the structures of this HCV viroporin as well as its drug-binding site using the latest nuclear magnetic resonance (NMR) technologies. The structure exhibits an unusual mode of hexameric assembly, where the individual p7 monomers, i, not only interact with their immediate neighbours, but also reach farther to associate with the i+2 and i+3 monomers, forming a sophisticated, funnel-like architecture. The structure also points to a mechanism of cation selection: an asparagine/histidine ring that constricts the narrow end of the funnel serves as a broad cation selectivity filter, whereas an arginine/lysine ring that defines the wide end of the funnel may selectively allow cation diffusion into the channel. Our functional investigation using whole-cell channel recording shows that these residues are critical for channel activity. NMR measurements of the channel–drug complex revealed six equivalent hydrophobic pockets between the peripheral and pore-forming helices to which amantadine or rimantadine binds, and compound binding specifically to this position may allosterically inhibit cation conduction by preventing the channel from opening. Our data provide a molecular explanation for p7-mediated cation conductance and its inhibition by adamantane derivatives.

(责任编辑:caoli)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1879594, encodeId=538a18e95943c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 10 02:48:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524118, encodeId=9aa215241183b, content=<a href='/topic/show?id=c28320934ab' target=_blank style='color:#2F92EE;'>#丙肝病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20934, encryptionId=c28320934ab, topicName=丙肝病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef511588776, createdName=lujian, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630398, encodeId=00b0163039804, content=<a href='/topic/show?id=3b97e4699c1' target=_blank style='color:#2F92EE;'>#离子通道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74699, encryptionId=3b97e4699c1, topicName=离子通道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83321501571, createdName=ysjykql, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=)]
    2013-09-10 智智灵药
  2. [GetPortalCommentsPageByObjectIdResponse(id=1879594, encodeId=538a18e95943c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 10 02:48:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524118, encodeId=9aa215241183b, content=<a href='/topic/show?id=c28320934ab' target=_blank style='color:#2F92EE;'>#丙肝病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20934, encryptionId=c28320934ab, topicName=丙肝病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef511588776, createdName=lujian, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630398, encodeId=00b0163039804, content=<a href='/topic/show?id=3b97e4699c1' target=_blank style='color:#2F92EE;'>#离子通道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74699, encryptionId=3b97e4699c1, topicName=离子通道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83321501571, createdName=ysjykql, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1879594, encodeId=538a18e95943c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 10 02:48:00 CST 2013, time=2013-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524118, encodeId=9aa215241183b, content=<a href='/topic/show?id=c28320934ab' target=_blank style='color:#2F92EE;'>#丙肝病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20934, encryptionId=c28320934ab, topicName=丙肝病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef511588776, createdName=lujian, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630398, encodeId=00b0163039804, content=<a href='/topic/show?id=3b97e4699c1' target=_blank style='color:#2F92EE;'>#离子通道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74699, encryptionId=3b97e4699c1, topicName=离子通道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83321501571, createdName=ysjykql, createdTime=Mon Jul 29 01:48:00 CST 2013, time=2013-07-29, status=1, ipAttribution=)]

相关资讯

JH:慢性丙型肝炎患者病毒学治愈后肝纤维化可缓慢消退

慢性丙型肝炎既是一种病毒性感染疾病,也是一种肝纤维化疾病。对于实现持续病毒学应答(SVR)且伴有肝纤维化患者,仍存在发生并发症的可能。由于无法反复对患者进行肝活检,因此,还没有相应的研究对慢性丙型肝炎治疗前后肝纤维化的动力学特征进行评估。Fibrotest已被确证是表征肝纤维化进展和消退的生物标志物,具有与肝活检相当的预测价值。 基于上述情况,来自法国巴黎肝脏中心的Thierry Poynard

J HEPATOL:多学科支持计划提高慢性丙肝患者依从性及抗病毒治疗有效性

对于慢性丙型肝炎(CHC)患者来说,坚持抗病毒治疗对于获得持续病毒学应答(SVR)是非常重要的。因此,来自西班牙Hospital del Mar医院肠胃病学部门的José A. Carrión博士及其同事展开一项研究,旨在评估了一项多学科支持计划(MSP)对于提高CHC病患依从性和增加聚乙二醇干扰素α-2a和利巴韦林治疗有效性的作用,该计划以已发表的HIV治疗经验为依据。该研究结果在线发表于201

JH:根据慢性丙肝患者肌苷三磷酸酶基因多态性可预测严重贫血的发生

贫血是丙型肝炎三联疗法——特拉匹韦(TVR)联合聚乙二醇干扰素(PEG-IFN)α和利巴韦林(RBV)的常见副作用之一。相比于单独使用PEG-IFNα和RBV,联用TVR的贫血发生率更高。因此,来自日本九州大学医院的Jun Hayashi教授(MD,PhD)等人展开一项研究,研究结果在线发表于2013年5月28日的Journal of Hepatology(《肝脏病学杂志》)上。作者发现,慢性丙型

DDW 2013:NAFLD患者死亡危险因素仍然不明

      在2013消化疾病周(DDW)上公布的一项研究显示,非酒精性脂肪性肝病(NAFLD)患者的死亡因素包括老年、男性、躯干性肥胖和高密度脂蛋白胆固醇(HDL-C)水平低,换言之,与心血管疾病死亡和其他原因死亡的危险因素相同。另一方面,NAFLD患者的丙氨酸转氨酶(ALT)水平升高与死亡或其他不良结局风险增加无关,这意味着研究者需更

中国丙型肝炎流行病学状况与反思

       丙型肝炎是由HCV 感染而导致的一种传播途径明确、起病隐匿、慢性化程度高的疾病。HCV 感染呈全球性流行状态,是导致肝硬化和肝癌的最主要病因。最近世界卫生组织公布的数据表明,HCV 全球流行率为3% ,大约有1.7 亿人感染HCV 。而每年新发病例约3.5 万。   HCV 的感染率在不同国家、地区之间存在较大差异。世界范围内以埃及的流行

FDA批准雅培HCV基因型检测试剂盒上市

  2013年6月20日,美国食品与药物管理局(FDA)批准了可检测到患者携带的丙型肝炎病毒(HCV)基因型的试剂盒(Abbott RealTime HCV Genotype II)上市,该试剂盒可对感染者的血清或血浆标本鉴别出基因型1、1a、1b、2、3、4和5。 该检测方法获准用于已知的HCV慢性感染者的鉴别诊断,而不用于血液遗传物质、血制品或组织供者的